L-Threonine

We are L-Threonine CAS:72-19-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


L-Threonine
 
An essential amino acid in human. It is widely used as an ingredient in infusion and infant formula.

Cas.No	72-19-5
Assay	99.0-101.0%
Specification	White crystals or crystalline powder, odorless or slightly characteristic odor, slightly sweet taste
Applications	Infusion
Packaging	25kg&50kg
Pharmacopeia	JP,USP,EP,FCC
STORAGE	Controlled room temperature in tight container

 
SPECIFICATION AND PROCEDURE

State of solution (Transmittance)	Not Less Than 98.0%
pH	5.0～6.5
Specific rotation[α]20D	-27.6～-29.0°
Specific rotation[α]25D	-26.7～-29.1°
Ammonium (NH4)	Not More Than 0.020%
Chloride (Cl)	Not More Than 0.020%
Sulfate (SO4)	Not More Than 0.020%
Iron (Fe)	Not More Than 10 ppm
Heavy metals (Pb)**	Not More Than 10 ppm
Arsenic (As2O3)	Not More Than 1 ppm
Loss on drying	Not More Than 0.20%
Residue on ignition	Not More Than 0.10%
Related substances	Not More Than 0.5%
Endotoxin*	Less Than 6.0 EU/g
Assay (dry basis)	99.0～101.0%

· * The endotoxin-certified grade will be supplied on request.
· ** FCC grade (Lead : Not More Than 5 mg/kg) will be supplied on request.
· This product meets requirements of residual solvents listed in the current JP, USP and EP.
 




Related News: The injection has previously proven to be as effective as standard daily pills with three active ingredients when administered monthly and also once every two months.dimethyl-bis[[methyl(diphenyl)silyl]oxy]silane Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.1-naphthyl isothiocyanate Pharmaceutical intermediates and APIs belong to the fine chemical industry.2-bromo-1-cyclopropyl-2-(2-fluorophenyl)ethanone CAS:204205-33-4 The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term.The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.